Analysts rate Amylyx Pharmaceuticals Inc. (AMLX:NSD) with a Strong Buy rating and a $37 target

Citigroup maintains the $50 AMLX stock price target and rates it as a Buy.

Based on the Amylyx Pharmaceuticals Stock Forecast from 2 analysts, the average analyst AMLX stock price target is USD 37.29 over the next 12 months. Amylyx Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AMLX stock forecast is Bearish, which is based on 1 positive signal and 3 negative signals. At the last closing, AMLX stock price was USD 31.16AMLX stock price has changed by +2.20% over the past week, +13.08% over the past month and +0.00% over the last year.

The Amylyx Pharmaceuticals Inc stock forecasts from 11 Crowd Analysts, has the average Crowd target for Amylyx Pharmaceuticals Inc at USD 36.47 over the next 12 months. Amylyx Pharmaceuticals Inc’s average Crowd Rating is a Strong Buy.


About Amylys Pharmaceuticals Inc. (AMLX:NSD):

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.


Recent Analyst Ratings:

Maintains Citigroup Buy USD 48 » USD 50 2022-10-03
Maintains Goldman Sachs Neutral USD 22 » USD 40 2022-09-09
Maintains Citigroup Buy USD 35 » USD 48 2022-09-08
Maintains Citigroup Buy USD 33 » USD 37 2022-07-06
Maintains Citigroup Buy USD 32 » USD 33 2022-06-14
Upgrade Citigroup Buy USD 32 2022-06-06
Initiates Coverage On Citigroup Buy USD 21 2022-05-25
Initiates Coverage On Evercore ISI Outperform 2022-02-02
Initiates Coverage On HC Wainwright Buy USD 35 2022-02-01
Initiates Coverage On Goldman Sachs Buy USD 36 2022-02-01
Initiates Coverage On SVB Leerink Outperform USD 50 2022-02-01


What we like:

High market capitalization:

Amylyx stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.


What we don’t like:

Overpriced compared to book value:

AMLX stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

Amylyx Pharmaceuticals had negative total cash flow in the most recent four quarters.

Negative free cash flow:

Amylyx Pharmaceuticals had negative total free cash flow in the most recent four quarters.